Mobile cardiac monitoring is one of the most advanced areas in med tech when it comes to wireless, remote tracking of patients. InfoBionic is hoping to take the technology to the next level by combining three different kinds of cardiac arrhythmia monitoring onto a single system that provides real-time, cloud-based patient data.
French radiopharmaceutical startup Advanced Accelerator Applications has filed for an IPO to raise up to $100 million. It already markets a half-dozen molecular imaging agents and is raising the money, at least in part, to gain pivotal data and regulatory approval for its first therapeutic.
Shervin Pishevar, one of the earlier backers of new-age taxi service Uber, is throwing his support behind San Diego startup Cue, which is developing a home-enabled diagnostic for testing for testosterone, fertility, inflammation, vitamin D and influenza.
More than 500 Pennsylvania-based Shire workers are shipping up to Boston in a move CEO Flemming Ornskov says will "streamline operations and drive further efficiencies."
Just after Zoetis kicked off its first-ever Investor Day at the New York Stock Exchange on Tuesday, trading in the company's stock was halted unexpectedly midday, when its financial forecasts were released earlier than the company had planned.
Alfred Mann aims to transform insulin administration for diabetics with Mannkind and its inhaled formulation, flying in the face of a host of skeptics who remember the prior market failure of Pfizer's inhaled insulin, Exubera. With one of his latest companies, Second Sight, Mann is aiming even higher--to cure blindness.
Medtronic's fastest growing business is in diabetes, which gained 10% to $430 million in the most recent quarter over a year ago. Now the medical device giant is looking to expand beyond its dominance in Type 1 diabetes that is based on the success of its insulin pump MiniMed. During an earnings call, Medtronic disclosed that it reorganized its diabetes group last quarter.
Japan's Terumo, the country's largest medical device maker, will soon offer bonds worth ¥100 billion ($857 million), which would be the country's largest bond offering since May, when two other Japanese companies raised that amount, Bloomberg reports.
NeuroSigma released top-line data for its noninvasive neuromodulation device to treat major depressive disorder. Next, the company plans a large, multicenter, double-blind clinical trial in this indication and may use that data to seek FDA approval.
As the med tech industry zeroes in on next-generation surgical sealants, Israeli startup LifeBond is raising $25 million to support development of its bio-surgical glue for postoperative tissue repair.